Amneal Pharmaceuticals (AMRX) EBT (2017 - 2026)

Amneal Pharmaceuticals' EBT history runs 10 years deep, the most recent figure standing at $80.2 million for Q1 2026.

• On a quarterly basis, EBT rose 113.88% year-over-year to $80.2 million in Q1 2026; TTM through Mar 2026 was $181.9 million, a 213.65% increase from a year earlier, with the FY2025 full-year figure at $139.2 million, up 353.05% from the prior year.
• EBT climbed to $80.2 million in Q1 2026 per AMRX's latest filing, from $55.2 million in the prior quarter.
• Across five years, EBT topped out at $80.2 million in Q1 2026 and bottomed at -$232.7 million in Q2 2022.
• The 5-year median for EBT is $2.2 million (2022), against an average of -$7.3 million.
• Biggest YoY gain for EBT was 953.07% in 2023; the steepest drop was 990.28% in 2023.
• Year by year, EBT stood at -$7.7 million in 2022, then slumped by 990.28% to -$83.5 million in 2023, then jumped by 81.65% to -$15.3 million in 2024, then jumped by 460.57% to $55.2 million in 2025, then surged by 45.15% to $80.2 million in 2026.
• Per Business Quant, the three latest AMRX EBT figures stand at $80.2 million (Q1 2026), $55.2 million (Q4 2025), and -$5.2 million (Q3 2025).